Claims
- 1. A compound, or enantiomer, stereoisomer, rotamer, tautomer, racemate or prodrug of said compound, or pharmaceutically acceptable salt or solvate of said compound, or pharmaceutically acceptable salt or solvate of said prodrug, said compound having the general structure shown in Formula I:
- 2. The compound of claim 1, wherein R1 is selected from the following:
- 3. The compound of claim 2, wherein R3 is selected from the group consisting of:
- 4. The compound of claim 3, wherein R3 is selected from the group consisting of the following moieties:
- 5. The compound of claim 4, wherein Z is N and R4 is H.
- 6. The compound of claim 5, wherein W is C═O.
- 7. The compound of claim 6, wherein Y is selected from the following moieties:
- 8. The compound of claim 7, wherein Y is selected from the group consisting of:
- 9. The compound of claim 8, wherein Y is selected from the group consisting of:
- 10. The compound of claim 9, wherein R2 is selected from the group consisting of the following moieties:
- 11. The compound of claim 9, wherein R2 is selected from the group consisting of the following moieties:
- 12. The compound of claim 10, wherein the moiety:
- 13. The compound of claim 11, wherein the moiety:
- 14. The compound of claim 10, wherein the moiety
- 15. The compound of claim 11, wherein the moiety:
- 16. A pharmaceutical composition comprising as an active ingredient at least one compound of claim 1.
- 17. The pharmaceutical composition of claim 16 for use in treating disorders associated with HCV.
- 18. The pharmaceutical composition of claim 16 additionally comprising at least one pharmaceutically acceptable carrier.
- 19. The pharmaceutical composition of claim 18, additionally containing ant least one antiviral agent.
- 20. The pharmaceutical composition of claim 19, still additionally containing an interferon or pegylated interferon.
- 21. The pharmaceutical composition of claim 20, wherein said at least one antiviral agent is ribavirin and said interferon is α-interferon.
- 22. A method of treating disorders associated with the HCV protease, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound of claim 1.
- 23. The method of claim 22, wherein said administration is subcutaneous.
- 24. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV protease.
- 25. A method of preparing a pharmaceutical composition for treating the disorders associated with the HCV protease, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.
- 26. The compound of claim 1, wherein said compound is selected from the group consisting of:
- 27. A pharmaceutical composition for treating disorders associated with the HCV protease, said composition comprising therapeutically effective amount of one or more compounds in claim 26 and a pharmaceutically acceptable carrier.
- 28. The pharmaceutical composition of claim 27, additionally containing at least one antiviral agent.
- 29. The pharmaceutical composition of claim 27, still additionally containing an interferon or a pegylated interferon.
- 30. The pharmaceutical composition of claim 28, wherein said antiviral agent is ribavirin and said interferon is α-interferon.
Parent Case Info
[0001] This patent application claims priority from U.S. provisional patent application Serial No. 60/350,931, filed Jan. 23, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60350931 |
Jan 2002 |
US |